---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-099631"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:32:21.495764+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology reports 49% confirmed ORR with onvansertib+SoC in Phase 2 mCRC trial; Q2 cash $71M

## Summary
- Confirmed ORR 49% (30mg onvansertib+SoC) vs 30% control in ITT population (N=110); early PFS trend favoring 30mg.
- Onvansertib well-tolerated; neutropenia most common grade 3+ AE; no unexpected toxicities.
- Q2 operating expenses $14.9M (vs $12.7M); cash and investments $71.0M; runway into Q1 2027.
- Appointed Dr. Roger Sidhu as CMO; completed enrollment in 41-site CRDF-004 trial.
- Company expects to provide update on first-line mCRC program by Q1 2026.

## SEC filing metadata
- accession: 0000950170-25-099631
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000095017025099631/0000950170-25-099631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000095017025099631/crdf-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-099631
- JSON: https://secwatch.observer/filing/0000950170-25-099631.json
- Plain text: https://secwatch.observer/filing/0000950170-25-099631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.